/
CCCC
$4.08+$0.18 (+4.62%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$479.8M
123M shares
52-week range
$1.69 – $5.17
69% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-34.69
C4 Therapeutics, Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
www.c4therapeutics.com- Employees
- 104
- IPO / List date
- Oct 2, 2020
- HQ
- WATERTOWN, MA
Held by traders on TradeandTell
No one on the platform currently holds CCCC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,461,815 | $6.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CCCC yet.
